Gustavo Dufort
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gustavo Dufort has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
A Dabezies
Pediatric Hemato–Oncology Department, Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
1 shared publicationA Incoronato
Pediatric Hemato–Oncology Department, Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
1 shared publicationA Tiscornia
Department of Transfusion Medicine, Centro Hospìtalario Pereira Rossell, Montevideo, Uruguay
1 shared publicationAgustín Dabezies
1 shared publication- Arne Riedlinger
Department of Pediatrics, Charité - Universitätsmedizin, Berlin, Germany
1 shared publication B Boggia
Department of Transfusion Medicine, Centro Hospìtalario Pereira Rossell, Montevideo, Uruguay
1 shared publication
Latest Publications
- 18 July 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (5) , 663-668
Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay
- 18 July 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (5) , 663-668
Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay
- Open Access
- 1 June 2010
- Published by Sociedad Chilena de Pediatria in Revista chilena de pediatría
- Vol. 81 (3) , 275-276
Trasplante de Progenitores Hematopoyéticos en Pediatría: 10 Años de Experiencia
- 1 June 2010
- Published by Sociedad Chilena de Pediatria in Revista chilena de pediatría
- Vol. 81 (3) , 275-276
Open AccessTrasplante de Progenitores Hematopoyéticos en Pediatría: 10 Años de Experiencia
- Open Access
- 23 October 2009
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 7 (1) , 92
Measuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation
Background: Disease-specific quality of life (QoL) measures have enhanced the capacity of outcome measures to evaluate subtle changes and differences between groups. However, when the specific disease is rare, the cohort of patients is small and international collaboration is often necessary to accomplish meaningful research. As many of the QoL measures have been developed in North American English, they require translation to ensure their usefulness in a multi-cultural and/or international society. Published guidelines provide formal methods to achieve cross-culturally comparable versions of a QoL tool. However, these guidelines describe a rigorous process that is not always feasible, particularly in rare disease groups. The objective of this manuscript is to describe the process that was developed to achieve accurate cross-cultural translations of a disease-specific QoL measure, to overcome the challenges of a small sample size, i.e. children with a rare disorder. Procedure: A measurement study was conducted in the United Kingdom (UK), France, Germany and Uruguay, during which the validated measure was translated into the languages of the respective countries. Results: This is a report of a modified, child-centric, cross-cultural translation and adaptation process in which culturally appropriate and methodologically valid translations of a disease-specific QoL measure, the Kids' ITP Tools (KIT), were performed in children with immune thrombocytopenic purpura (ITP). The KIT was translated from North American English into UK English, French, German, and Spanish. Conclusion: This study was a successful international collaboration. The modified process through which culturally appropriate and methodologically valid translations of QoL measures may be achieved in a pediatric population with a relatively rare disorder is reported.
- 23 October 2009
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 7 (1) , 92
Open AccessMeasuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation
Background: Disease-specific quality of life (QoL) measures have enhanced the capacity of outcome measures to evaluate subtle changes and differences between groups. However, when the specific disease is rare, the cohort of patients is small and international collaboration is often necessary to accomplish meaningful research. As many of the QoL measures have been developed in North American English, they require translation to ensure their usefulness in a multi-cultural and/or international society. Published guidelines provide formal methods to achieve cross-culturally comparable versions of a QoL tool. However, these guidelines describe a rigorous process that is not always feasible, particularly in rare disease groups. The objective of this manuscript is to describe the process that was developed to achieve accurate cross-cultural translations of a disease-specific QoL measure, to overcome the challenges of a small sample size, i.e. children with a rare disorder. Procedure: A measurement study was conducted in the United Kingdom (UK), France, Germany and Uruguay, during which the validated measure was translated into the languages of the respective countries. Results: This is a report of a modified, child-centric, cross-cultural translation and adaptation process in which culturally appropriate and methodologically valid translations of a disease-specific QoL measure, the Kids' ITP Tools (KIT), were performed in children with immune thrombocytopenic purpura (ITP). The KIT was translated from North American English into UK English, French, German, and Spanish. Conclusion: This study was a successful international collaboration. The modified process through which culturally appropriate and methodologically valid translations of QoL measures may be achieved in a pediatric population with a relatively rare disorder is reported.